M&A: Oncotelic Therapeutics, Inc.

Form Type: 8-K

Filing Date: 2025-01-02

Corporate Action: Merger

Type: Update

Accession Number: 000149315225000028

Comments: On December 31, 2024, Oncotelic Therapeutics, Inc. and Mosaic ImmunoEngineering, Inc. mutually agreed to extend the date for completing a proposed reverse merger to no later than June 30, 2025. This update follows a previous binding term sheet entered into on April 26, 2024, which outlined the terms of the proposed transaction. The term sheet was initially set to expire 90 days after its execution and was extended in prior filings. The decision to continue pursuing the proposed transaction reflects the companies' interests, although there are no guarantees of a definitive agreement being reached.

Document Link: View Document